+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin discontinuation in high-risk patients: a systematic review of the evidence



Statin discontinuation in high-risk patients: a systematic review of the evidence



Current Pharmaceutical Design 17(33): 3669-3689



Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD), the leading cause of death worldwide. Since the late 1980s, statins have emerged as effective lipid-lowering therapies and are now widely used to protect against and slow the progression of CVD and cerebrovascular disease. However, there is a significant gap between disease improvement in clinical trials and daily practice possibly attributable to poor adherence with statin therapy. High discontinuation rates were reported in primary and secondary prevention. This systematic review aims to summarize the current literature regarding the association between statin therapy discontinuation and cardiovascular and cerebrovascular events and all-cause mortality in high-risk patients. Available English literature was reviewed using Medline, Embase, Web of Sciences and the Cochrane Library; 39 studies were identified. In primary and secondary prevention, as well as perioperatively, non-adherence or discontinuation of statin therapy was associated with detrimental effects on cardiovascular and cerebrovascular outcomes, including disease severity and mortality. Importantly, some studies reported that very low adherence and discontinuation was associated with worse outcomes than never using statins. In conclusion, non-adherence and discontinuation of statin therapy significantly increased the incidence of cardiovascular and cerebrovascular events as well as all-cause mortality in high-risk patients. Patients would therefore benefit from closer adherence assessment and education programs aimed at increasing awareness of the risk associated with discontinuation of statin therapy.

(PDF emailed within 1 workday: $29.90)

Accession: 055911063

Download citation: RISBibTeXText

PMID: 22074437


Related references

Patient characteristics and statin discontinuation-related factors during treatment of hypercholesterolemia: an observational non-interventional study in patients with statin discontinuation (STAY study). Turk Kardiyoloji Dernegi Arsivi 44(1): 53-64, 2016

Risk factors for discontinuation of statin medications: Evidence from a large national pharmacy claims database. 2007

Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk for delirium: a systematic review of quantitative evidence protocol. Jbi Database of Systematic Reviews and Implementation Reports 13(7): 83-92, 2016

Systematic review: Very-low-strength evidence suggests that combining ezetimibe or fibrate with statins is no more effective than high-dose statin monotherapy for reducing all-cause mortality. Evidence-Based Medicine 15(2): 52-53, 2010

Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Current Medical Research and Opinion 27(6): 1191-1210, 2011

High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. Bmj Open 5(5): E006886-E006886, 2016

Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management 7(): 157-166, 2011

Perioperative statin therapy in patients at high risk for cardiovascular morbidity undergoing surgery: a review. British Journal of Anaesthesia 114(1): 44-52, 2015

Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 31(7): 1779-1784, July, 2000

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. American Journal of Cardiology 89(4): 390-394, February 15, 2002

Economic Evaluation Of A Pharmacogenomic Test For Statin-Induced Myopathy In Cardiovascular High-Risk Patients Initiating A Statin. Value in Health 18(7): A396-A396, 2015

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. Molecular Diagnosis & Therapy (): -, 2016

Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Annals of the Rheumatic Diseases 70(6): 1020-1024, 2011

A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression. Health Technology Assessment 17(42): 1-274, 2014